Choosing a Treatment for Patients at the Time a Fracture is Presented

The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices...

Full description

Saved in:
Bibliographic Details
Published in:Current osteoporosis reports 2011-09, Vol.9 (3), p.156-159
Main Author: Tanner, S. Bobo
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Denosumab
Diphosphonates - therapeutic use
Epidemiology
Fractures, Spontaneous - etiology
Fractures, Spontaneous - prevention & control
Humans
Medicine
Medicine & Public Health
Orthopedics
Osteoporosis - complications
Osteoporosis - drug therapy
RANK Ligand - therapeutic use
Secondary Prevention
Teriparatide - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53
cites cdi_FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53
container_end_page 159
container_issue 3
container_start_page 156
container_title Current osteoporosis reports
container_volume 9
creator Tanner, S. Bobo
description The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.
doi_str_mv 10.1007/s11914-011-0061-4
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_881087486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>881087486</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53</originalsourceid><addsrcrecordid>eNp9kMFOwzAMhiMEYmPwAFxQbpwKdpp22RFNGyBNYodxjpLW2Tqt7UjaA29Ppg6OnGzJn3_ZH2P3CE8IMH0OiDOUCSAmADkm8oKNMZMyEULi5blHNU1H7CaEPYAQKNNrNhKYZ9kshTFbzHdtG6pmyw3feDJdTU3HXev52nRV7AM3He92xDdVTRFaelN0vSdeBb72FCJC5S27cuYQ6O5cJ-xzudjM35LVx-v7_GWVFKmIp1hryhSsVOimmM6syzOyzhlJpHJpRQHGooTUOYlUKouUAWCeC0m2dCZLJ-xxyD369qun0Om6CgUdDqahtg9aKQQ1lSqPJA5k4dsQPDl99FVt_LdG0Cd5epCnozx9kqdl3Hk4p_e2pvJv49dWBMQAhDhqtuT1vu19Ez_-J_UHQvJ5OA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881087486</pqid></control><display><type>article</type><title>Choosing a Treatment for Patients at the Time a Fracture is Presented</title><source>Springer Link</source><creator>Tanner, S. Bobo</creator><creatorcontrib>Tanner, S. Bobo</creatorcontrib><description>The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.</description><identifier>ISSN: 1544-1873</identifier><identifier>EISSN: 1544-2241</identifier><identifier>DOI: 10.1007/s11914-011-0061-4</identifier><identifier>PMID: 21655930</identifier><language>eng</language><publisher>New York: Current Science Inc</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Denosumab ; Diphosphonates - therapeutic use ; Epidemiology ; Fractures, Spontaneous - etiology ; Fractures, Spontaneous - prevention &amp; control ; Humans ; Medicine ; Medicine &amp; Public Health ; Orthopedics ; Osteoporosis - complications ; Osteoporosis - drug therapy ; RANK Ligand - therapeutic use ; Secondary Prevention ; Teriparatide - therapeutic use</subject><ispartof>Current osteoporosis reports, 2011-09, Vol.9 (3), p.156-159</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53</citedby><cites>FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21655930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tanner, S. Bobo</creatorcontrib><title>Choosing a Treatment for Patients at the Time a Fracture is Presented</title><title>Current osteoporosis reports</title><addtitle>Curr Osteoporos Rep</addtitle><addtitle>Curr Osteoporos Rep</addtitle><description>The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Denosumab</subject><subject>Diphosphonates - therapeutic use</subject><subject>Epidemiology</subject><subject>Fractures, Spontaneous - etiology</subject><subject>Fractures, Spontaneous - prevention &amp; control</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Orthopedics</subject><subject>Osteoporosis - complications</subject><subject>Osteoporosis - drug therapy</subject><subject>RANK Ligand - therapeutic use</subject><subject>Secondary Prevention</subject><subject>Teriparatide - therapeutic use</subject><issn>1544-1873</issn><issn>1544-2241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kMFOwzAMhiMEYmPwAFxQbpwKdpp22RFNGyBNYodxjpLW2Tqt7UjaA29Ppg6OnGzJn3_ZH2P3CE8IMH0OiDOUCSAmADkm8oKNMZMyEULi5blHNU1H7CaEPYAQKNNrNhKYZ9kshTFbzHdtG6pmyw3feDJdTU3HXev52nRV7AM3He92xDdVTRFaelN0vSdeBb72FCJC5S27cuYQ6O5cJ-xzudjM35LVx-v7_GWVFKmIp1hryhSsVOimmM6syzOyzhlJpHJpRQHGooTUOYlUKouUAWCeC0m2dCZLJ-xxyD369qun0Om6CgUdDqahtg9aKQQ1lSqPJA5k4dsQPDl99FVt_LdG0Cd5epCnozx9kqdl3Hk4p_e2pvJv49dWBMQAhDhqtuT1vu19Ez_-J_UHQvJ5OA</recordid><startdate>201109</startdate><enddate>201109</enddate><creator>Tanner, S. Bobo</creator><general>Current Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201109</creationdate><title>Choosing a Treatment for Patients at the Time a Fracture is Presented</title><author>Tanner, S. Bobo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Denosumab</topic><topic>Diphosphonates - therapeutic use</topic><topic>Epidemiology</topic><topic>Fractures, Spontaneous - etiology</topic><topic>Fractures, Spontaneous - prevention &amp; control</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Orthopedics</topic><topic>Osteoporosis - complications</topic><topic>Osteoporosis - drug therapy</topic><topic>RANK Ligand - therapeutic use</topic><topic>Secondary Prevention</topic><topic>Teriparatide - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tanner, S. Bobo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current osteoporosis reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tanner, S. Bobo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Choosing a Treatment for Patients at the Time a Fracture is Presented</atitle><jtitle>Current osteoporosis reports</jtitle><stitle>Curr Osteoporos Rep</stitle><addtitle>Curr Osteoporos Rep</addtitle><date>2011-09</date><risdate>2011</risdate><volume>9</volume><issue>3</issue><spage>156</spage><epage>159</epage><pages>156-159</pages><issn>1544-1873</issn><eissn>1544-2241</eissn><abstract>The occurrence of a fragility fracture is an opportunity to recognize osteoporosis and begin treatment to reduce the risk of another fracture. However, selecting the treatment may have an impact on the incident fracture and this requires careful consideration of the patient and the treatment choices. There is no consensus regarding the management of osteoporosis at the time of an incident fracture. This review will consider the treatment options after a fragility fracture.</abstract><cop>New York</cop><pub>Current Science Inc</pub><pmid>21655930</pmid><doi>10.1007/s11914-011-0061-4</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1544-1873
ispartof Current osteoporosis reports, 2011-09, Vol.9 (3), p.156-159
issn 1544-1873
1544-2241
language eng
recordid cdi_proquest_miscellaneous_881087486
source Springer Link
subjects Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Denosumab
Diphosphonates - therapeutic use
Epidemiology
Fractures, Spontaneous - etiology
Fractures, Spontaneous - prevention & control
Humans
Medicine
Medicine & Public Health
Orthopedics
Osteoporosis - complications
Osteoporosis - drug therapy
RANK Ligand - therapeutic use
Secondary Prevention
Teriparatide - therapeutic use
title Choosing a Treatment for Patients at the Time a Fracture is Presented
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Choosing%20a%20Treatment%20for%20Patients%20at%20the%20Time%20a%20Fracture%20is%20Presented&rft.jtitle=Current%20osteoporosis%20reports&rft.au=Tanner,%20S.%20Bobo&rft.date=2011-09&rft.volume=9&rft.issue=3&rft.spage=156&rft.epage=159&rft.pages=156-159&rft.issn=1544-1873&rft.eissn=1544-2241&rft_id=info:doi/10.1007/s11914-011-0061-4&rft_dat=%3Cproquest_cross%3E881087486%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3244-bbad30b481f7139bf65ebffa4ee864b2c0ab1403ff41ed8b1e50016624ebdfa53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=881087486&rft_id=info:pmid/21655930&rfr_iscdi=true